Eczema Prognosis

Short answer for parents: many toddlers improve a lot or clear by school age, but a sizeable minority do not, and “clear” often means “quiet for now”. Prospective birth cohorts are the best evidence because they follow every child, not just the ones who end up in clinic. In the German Multicenter Allergy Study (MAS; Illi et al., JACI 2004), 1,314 children were followed from birth to age 7. About 21.5% had Atopic Dermatitis in their first 2 years. Of these, 43.2% were in complete remission by age 3, 38.3% had an on-off (intermittent) pattern, and 18.7% had symptoms every single year. DermNet likewise says AD is usually worst between ages 2 and 4 and often improves or clears after that, but warns it is impossible to predict for an individual child and can return in adult life with irritant or occupational exposure. Across all ages, the Kim et al. meta-analysis (JAAD 2016; 45 studies, 110,651 subjects) found 80% of childhood AD no longer persisted 8 years after diagnosis and under 5% persisted at 20 years.

Multicenter Allergy Study [supports] Eczema Prognosis Atopic Dermatitis [relates] Eczema Prognosis

Not one disease course but several (Eczema Trajectories). Paternoster et al. (JACI 2018) modelled parent-reported rash in the UK ALSPAC cohort (9,894 children, to age 16.5) and the Dutch PIAMA cohort (3,652, to age 11). They found six reproducible patterns. Roughly 58–63% of children were unaffected or had only transient rash. The commonest eczema pattern was early-onset-early-resolving (12.9–15.4%): rash at 18–30 months that fell to about 10% by age 6–7, more common in boys and only weakly linked to later Asthma. Two groups had long-lasting disease: early-onset-persistent (4.9–7.3%; still ~50% with rash at 16.5) and early-onset-late-resolving (3.8–7.0%; fading to ~10% by 16.5). Two further groups started later: mid-onset (peak around 6) and late-onset (rising again around 12, more common in girls). For a toddler who already has eczema, this means the odds of clearing in early school years are real but not guaranteed. Persistent groups are about as large as the early-resolving group. The Swedish BAMSE cohort (Ballardini et al., JACI 2014; 3,208 children followed to 12) found that of children with persistent infantile eczema, 33.3% still had eczema, 17.2% had asthma and 43.9% had Allergic Rhinitis at age 12.

Eczema Trajectories [defines] Eczema Prognosis ALSPAC [supports] Eczema Trajectories BAMSE [supports] Eczema Prognosis

Predictors of persistence.

• Severity. It was the strongest predictor in MAS (adjusted cumulative OR 5.86 for a worse course). Three studies in Kim 2016 also tied severe AD to longer persistence. Severity is graded with SCORAD, EASI or POEM.
• Allergic sensitisation, for example to foods (Food Allergy). MAS found it raised the risk of a worse course (aOR 2.76), but Kim 2016 found no link (see conflict below).
• Filaggrin (FLG) null mutations. In ALSPAC these were most strongly linked to early-onset-persistent AD (OR 4.31, versus 2.1–2.3 for resolving groups). Abuabara 2019 also found FLG mutations commoner in childhood-onset eczema.
• Family history. A mother with AD (OR 3.16 for the persistent class) and parental asthma both raised the risk of persistence in ALSPAC/PIAMA.
• Age at onset. The evidence here points both ways (see conflict).
• Already-persistent disease. Kim found that eczema which has already lasted many years tends to keep going.
• Sex. Female sex was linked to persistent and late-onset patterns, and male sex to early-resolving eczema (Kim 2016; Paternoster 2018).

Filaggrin [worsens] Eczema Prognosis Food Allergy [relates] Eczema Prognosis

Conflict: [Kim et al., JAAD 2016] says 80% of childhood AD has remitted by 8 years after diagnosis and <5% persists at 20 years. [Margolis et al., JAMA Dermatol 2014, PEER registry] says >80% of children aged 2–26 still had symptoms or used treatment, and only half had a 6-month clear spell by age 20. [Abuabara et al., Allergy 2018] found AD prevalence barely falls after age 12 (−1%, not significant), and [Abuabara et al., JACI 2019, British 1958/1970 cohorts to age 42–50] found annual eczema prevalence of 5–15% with no clear decline by age, and only 38% of adults with active eczema had childhood onset. [Illi et al., JACI 2004, MAS] sits between them: 43% of early AD remitted fully by age 3 but 19% had symptoms every year to age 7. Differences likely reflect outcome definitions (remission vs any symptom-free period), recurrence after apparent clearance, adult-onset cases, and cohort selection (treated-patient registry vs population). Unresolved — add to open_questions.

Conflict: [Kim et al., JAAD 2016] says onset by age 2 predicts less persistent disease and that allergen sensitisation is not associated with persistence (P = .90). [Paternoster et al., JACI 2018, ALSPAC/PIAMA] says both long-lasting classes are early-onset and carry the strongest FLG and family-history links, and [Illi et al., JACI 2004, MAS] says atopic sensitisation is a major determinant of poor prognosis (aOR 2.76). [Medicina 2024 review] lists younger age at onset as a risk factor for atopic-march progression. Unresolved — add to open_questions.

Does the treatment you choose change the long-term outcome? No study in this vault shows that any treatment changes whether a child eventually outgrows eczema. Track A home remedies and Track B prescribed care both aim at control, not cure. Two common beliefs need separating:

• “Steroid creams drive eczema inward and cause asthma.” “Inducing asthma” is a recognised item of Steroid Phobia and is scored in the TOPICOP questionnaire (Moret et al., PLoS One 2013). The TOPICOP authors note that negative beliefs about Topical Corticosteroids are often not based on scientific findings. None of the cohorts reviewed here reports evidence that TCS use causes asthma. What does predict later asthma is the eczema itself: its severity, how long it lasts, early wheeze and sensitisation (Illi 2004; Paternoster 2018; Medicina 2024). In MAS, early AD without early wheeze or sensitisation carried no extra wheeze risk (aOR 1.11). The authors read the AD-plus-wheeze group as “a distinct phenotype rather than a progressive development from AD to asthma.” Under-treating out of fear mainly prolongs itch and sleep loss. evidence: weak (absence of evidence of harm, not a dedicated trial)
• “Treat early and hard to stop the atopic march.” This is the mirror-image hypothesis. If a leaky, inflamed barrier lets allergens in (Skin Barrier Dysfunction, Dual-Allergen Exposure Hypothesis), then fast control should reduce later allergy. It is biologically plausible but unproven. Emollients from birth did not prevent eczema in the BEEP Trial. Early allergen introduction (LEAP Trial) prevents only the specific food allergy. No trial has shown that good toddler eczema control with Emollient Therapy or TCS prevents later asthma or hay fever (Medicina 2024; see Atopic March). A sponsor-run, adult-dominated Dupilumab analysis reported fewer new allergic conditions, which is not toddler evidence.

The practical message is to treat for comfort, sleep and skin integrity now. Expect improvement in many children by school age, but do not assume it, and do not count a quiet spell as a cure.

Topical Corticosteroids [relates] Eczema Prognosis Steroid Phobia [contradicts] Topical Corticosteroids Atopic March [relates] Eczema Prognosis

Comorbidity outlook. Persistent and severe eczema carries the highest comorbidity risk. In ALSPAC/PIAMA, the early-onset-persistent class had the strongest links to asthma at 7, 11 and 13. All eczema classes had some raised asthma risk, but the data “did not support the presence of a specific trajectory from AD to asthma” (Paternoster 2018). This fits Belgrave 2014, where only ~7% of symptomatic children followed a march-like path. Long-standing scratching also leaves skin changes such as Lichenification, which signal chronic disease and take longer to settle.

Eczema Prognosis [relates] Asthma Eczema Prognosis [relates] Allergic Rhinitis Eczema Prognosis [relates] Lichenification

Connections

• Atopic Dermatitis — natural course of, source: Illi 2004; Kim 2016; DermNet
• Eczema Trajectories — six longitudinal subtypes define the range of outcomes, source: Paternoster 2018
• ALSPAC — UK birth cohort used for trajectory modelling, source: Paternoster 2018
• Multicenter Allergy Study — 43.2% remission by age 3; severity and sensitisation predict course, source: Illi 2004
• BAMSE — persistent infantile eczema → 33% eczema, 17% asthma, 44% rhinitis at 12, source: Ballardini 2014
• PEER Registry — >80% still symptomatic or treated at every age 2–26, source: Margolis 2014
• Filaggrin — FLG null mutations most strongly linked to early-onset-persistent AD (OR 4.31), source: Paternoster 2018
• Food Allergy — sensitisation predicts poorer course in MAS (contested by Kim 2016), source: Illi 2004
• Asthma — strongest with persistent AD; not a fixed march, source: Paternoster 2018; Illi 2004
• Allergic Rhinitis — 43.9% at 12 after persistent infantile eczema, source: Ballardini 2014
• Atopic March — early treatment preventing progression is unproven, source: Medicina 2024
• Topical Corticosteroids — no evidence they “drive eczema inward” or cause asthma, source: Moret 2013; Illi 2004
• Steroid Phobia — “inducing asthma” is a recognised steroid-phobia belief, source: Moret 2013 (TOPICOP)
• Lichenification — marker of chronic disease, source: DermNet
• SCORAD — severity, the strongest prognostic factor, is graded with SCORAD/EASI, source: Illi 2004
• Treatment Outcomes Comparison — neither track shown to change long-term course, source: Illi 2004